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In Switzerland, Pharmaceutical Medicine has existed as one of 46 physician specialties
accredited by the Federal Office of Public Health for more than 20 years. As a
medical-scientific discipline, our goal is to enable best possible therapeutic coverage
for the benefit of patients and society through a medical need-based development
and optimal use of medicinal products. The role of the specialist in Pharmaceutical
Medicine is to closely collaborate with various stakeholders of the healthcare system
in the context of the discovery, research, development and approval of new medicinal
products, as well as safe and effective use of new and established medicinal products
in daily clinical practice. The post-graduate training consists of 2 years of patient-related
clinical work, followed by 3 years of vocational training at certified training centers in
Pharmaceutical Medicine. This also includes completion of an academic post-graduate
diploma in Pharmaceutical Medicine (30 ECTS) according to the IFAPP/PharmaTrain
syllabus and a 1 day board exam. As part of an ongoing revision of the training
curriculum, we are developing a Swiss Catalog of Core Competencies in Pharmaceutical
Medicine (SC3-PM), based on the IFAPP competency framework for drug development
specialists in industry. In this article we discuss how we adapt the scope of the IFAPP
competency framework to better reflect such roles in academic institutions or regulatory
bodies in Switzerland.
Keywords: Pharmaceutical Medicine, competency-based, post-graduate training, board-certification, vocational
training, Switzerland
PHARMACEUTICAL MEDICINE TRAINING IN SWITZERLAND
On January 1, 1999, the Swiss Department of Health officially recognized Pharmaceutical Medicine
as a fully board-certified physician specialty in Switzerland. This marked a key milestone for the
Swiss Society of Pharmaceutical Medicine (SSPM). The SSPM was founded mid 1997 with the aim
of advancing the science and practice of Pharmaceutical Medicine, by developing and maintaining
competencies, ethics and integrity in order to provide the highest professional standards for
the benefit of the patients and public (Traber and Althaus, 2010). Today, Pharmaceutical
Medicine is one of 46 physician specialties accredited by the Swiss Department of Health
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(Swiss Institute for Post-Graduate Training and Continuous
Education, 2018c), and Switzerland is still one of the few
countries where such a board-certified physician specialty exists
(Nell, 2018).
A board-certified specialist title is the reference for the
post-graduate qualification of a physician in Switzerland and
is publicly disclosed in the national registry of medical
professionals (Federal Office of Public Health, 2018b). For most
specialties it is the pre-requisite to practicing independently
and being remunerated for related clinical activities. There are
no clinical or regulatory activities restricted to a physician
who is specialized in Pharmaceutical Medicine, however, the
title serves as evidence of the qualifications required by the
Swiss Clinical Trials Ordinance to act as sponsor-investigator
(Swiss Clinical Trials Ordinance, 2017).
Since its introduction, the training curriculum for
Pharmaceutical Medicine requires 2 years of patient care
related clinical training, followed by 3 years of vocational
training at certified training centers for Pharmaceutical
Medicine (reviewed in Traber and Althaus, 2010). This
general educational framework for postgraduate training for
physicians in Switzerland is governed by the Swiss Institute for
Post-Graduate Training and Continuous Medical Education
(Schweizerisches Institut für Weiter- und Fortbildung, SIWF),
while the SSPM is responsible for the subject specific content of
the curriculum (see Supplementary Figure S1) (Swiss Institute
for Post-Graduate Training and Continuous Education, 2018b).
Training centers are classified in four categories (A–D) based on
multiple parameters such as the number of board-certified (or
comparably qualified) educational staff as well as metrics and
infrastructure regarding various domains offered for training
from the broad spectrum of Pharmaceutical Medicine.
Historically, clinical trials were defined as the core element of
medical product development, which has been reflected in the
educational goals and requirements. Trainees had to demonstrate
at least 2 years of project level involvement in clinical trials and
training centers were classified based on number of CRFs actively
managed in phase I–IV trials, as well as metrics on adverse event
reports. Training center activity in the area of drug discovery,
pre-clinical development, pharmacological development and
public health had a lower weight. The main focus on clinical
trials has gradually been removed and since the last revision in
2016 all core areas are contributing now in a balanced way to the
vocational training for Pharmaceutical Medicine (Swiss Institute
for Post-Graduate Training and Continuous Education, 2018d)
(see Supplementary Table S2).
Each training site has to prepare its own concept for vocational
training based on the educational goals outlined in the current
training curriculum for Pharmaceutical Medicine (Swiss Institute
for Post-Graduate Training and Continuous Education, 2018d).
This serves as the basis for validation through a SIWF-led
expert panel (including one SSPM representative), which grants
approval of new training sites, renewal in case of change of
training center lead at an approved site, or general periodic audits
(at least every 7 years). Additionally, each trainee is required to
attend and document a minimum of 360 h of theoretical training
on the topics of discovery (12 h), pharmaceutical development
(16 h), pre-clinical development (24 h), clinical development
(150 h), pharmacovigilance (32 h), medical information (32 h),
drug regulations (46 h), socioeconomics and public health (24 h)
as well as management (24 h). This can be substituted by
successful completion of an academic post-graduate diploma
course following the IMI/PharmaTrain syllabus (PharmaTrain,
2018), which is offered in Switzerland by the European Center
for Pharmaceutical Medicine (ECPM) (European Center for
Pharmaceutical Medicine, 2018) at the University of Basel.
Learning progress is evaluated by the training center leads using
regular structured feedback and workplace related assessments
(at least four times per year) and documented in a central
e-logbook during the entire training period.
The curriculum allows a maximum of 1 year of training at an
accredited training center for Prevention Medicine and Public
Health, or in Clinical Pharmacology and Toxicology. Equally,
1 year research as part of an MD/PhD program, or under the
supervision of a certified study sponsor-investigator outside of
a training center for Pharmaceutical Medicine is accepted. No
more than 1.5 years of training outside of Switzerland can
be accounted for the curriculum. However, mutual recognition
of foreign specialty titles in Pharmaceutical Medicine exists
for countries with a similar training profile (e.g., Faculty of
Pharmaceutical Medicine, 2018).
Currently, board examination consists of an extensive
knowledge test (120 questions, multiple choice) followed by an
assessment based on a written essay on three open formulated
questions (2 h) and an interview based discussion (approx. 1 h)
covering a published clinical research paper as well as other topics
of Pharmaceutical Medicine. Under exceptional circumstances, a
specialist title can be granted based on merits due to pioneering
work in the field of Pharmaceutical Medicine.
A board-certified specialist has an obligation to complete 80 h
of continuous medical education (CME) per year. Of these at
least 50 h need to be testified through CME credits, of which half
need to be in the field of Pharmaceutical Medicine. Importantly,
CME credits in any other specialty can be recognized, if it
is linked to the therapeutic field of daily work (e.g., CME in
cardiology if involved in medicinal product development in
cardiovascular diseases). CME credits must be self-recorded in
an online system operated by the SIWF and completion of
above mentioned requirements need to be certified periodically
in 3 year intervals (Swiss Institute for Post-Graduate Training
and Continuous Education, 2018a).
TRENDS IN PHARMACEUTICAL
MEDICINE TRAINING IN SWITZERLAND
DURING THE PAST 20 YEARS
Over the past 20 years, more than 120 physicians have been
board-certified in Pharmaceutical Medicine (Supplementary
Figure S3). The average number of physicians completing their
training fluctuated around three to five per year. Only at time of
introduction of this specialty title (1999–2003), a higher number
of physicians working already in the field of pharmaceutical
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medicine were certified based on their “merits” or through
mutual recognition programs.
Initially, most specialists have been trained in industry,
however, over the past 10 years there has been a surge
in specialists trained at academic centers (Supplementary
Figure S4). This coincides with the emergence of clinical trial
units (CTUs) at university hospitals and other tertiary care
centers, followed by the establishment of the Swiss Clinical
Trial Organization (SCTO) in 2009 with the concomitant
improvement of clinical trial quality and metrics (Von
Niederhäusern et al., 2018). The number of certified training
centers for Pharmaceutical Medicine based in the academic
setting in Switzerland increased during this period from
one to three.
At the same time, the number of certified training centers
among the local affiliates of pharmaceutical companies declined
in Switzerland. This can be attributed to two key reasons: First,
a decline of physicians who select industry (and especially local
medical affairs departments of pharmaceutical company affiliates
in Switzerland) as a workplace for their post-graduate training.
The absence of a trainee for more than 3 years leads to suspension
of the training center certification. Second, several training
centers lost their accreditation despite the presence of potential
training candidates, because the head of the training center did
not have the required qualifications. Additionally, the trend for
internationalization and fragmentation of the different functions
(research and development, medical affairs, regulatory affairs,
pharmacovigilance, patient access, medical information), where
reporting and governance structures are no longer maintained at
local level, increases complexity for country medical directors to
prepare and maintain a vocational training concept according to
the curriculum.
Several pharmaceutical companies have their international
head quarters or large operating centers including research
and development, or medical affairs organizations based in
Switzerland. Despite substantial investment in training and
mentoring of employees, none of these are certified sites
for vocational training. Administrative hurdles and constraints
imposed by the Swiss post-graduate training process for
physicians together with a lack of corporate interest and
perceived benefit have anecdotally been quoted as reasons
not to pursue.
EVOLUTION TO A COMPETENCY-BASED
TRAINING CURRICULUM FOR
PHARMACEUTICAL MEDICINE IN
SWITZERLAND
The training curriculum itself is also subject to a regular
accreditation process according to the Swiss Medical Professions
Act. This was most recently conducted between February 2016
and August 2018. It involved a critical self-reflection on the
purpose and content of the post-graduate training curriculum
through the SSPM, as well as an external review by independent
international experts. During this process we identified the need
to further evolve the original knowledge based curriculum with
“learning based” to a competency- based approach, aligned with
the updated IFAPP syllabus and competency statement (IFAPP,
2016). Accreditation was granted and an updated curriculum has
to be in place by end of 2019, which addresses the following
additional requirements (Federal Office of Public Health, 2018a):
(a) A vision and mission statement has to be defined, which
outlines the role of a specialist in Pharmaceutical Medicine
and his or her interactions with other stakeholders of the
healthcare system regarding to contribution of care.
(b) A plan or method to maintain the high quality of training
in order to react and adapt to the evolving environment
in healthcare.
The SSPM has established a new working group involving
the heads of selected training centers to update the training
curriculum through a series of workshops and off-line review
cycles. Here we outline the core aspects of the revised curriculum
and share the proposed changes.
The Role of the Specialist in
Pharmaceutical Medicine in the Swiss
Healthcare System
As a medical-scientific discipline, our vision is to provide the
best possible therapeutic coverage for the benefit of patients
and society through a medical need-based development and
optimal use of medicinal products. The role of the specialist in
Pharmaceutical Medicine is to closely collaborate with various
stakeholders of the healthcare system in the context of the
discovery, research, development and approval of new medicinal
products, as well as safe and effective use of new and established
medicinal products in daily clinical practice. The patient-centric,
evidence-based decision process has a direct influence on the
therapeutic coverage of patients, potentially beyond our national
healthcare system.
A patient-centric development of medicinal products
has to adhere to stringent legal, ethical and qualitative
requirements with regards to the planning and conduct
of clinical trials, accurate interpretation of pre-clinical,
toxicological, pharmacological and clinical results with
appropriate consideration of the benefit-risk profile and
socio-economic aspects. The knowledge and competence
in preparing documents for regulatory (e.g., clinical trial
applications, marketing authorization application, periodic
safety update reports) or reimbursement (e.g., health technology
assessments) submissions, the continuous improvement of
therapeutic benefit through appropriate medical information,
supply coverage, appropriate risk management through the
whole lifecycle of medicinal products requires expertise in
Pharmaceutical Medicine. Therefore, the work of specialists in
Pharmaceutical Medicine is valuable:
- In translational medicine and clinical research at academic
centers and hospitals (incl. dedicated CTUs and general
clinical services).
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- At manufacturers and distributors of pharmaceutical
or biomedical products and their service providers
(including contract research organizations
and consultancies).
- With regulatory and related competent authorities (e.g.,
Swissmedic, Federal Office of Public Health).
Revision to the Curriculum Structure
While the general structure of post-graduate training will
remain the same (Figure 1), we propose a few procedural
changes to strengthen the medical-scientific character of
our discipline. A university-based post-graduate course with
the completion of the Basis Diploma in Pharmaceutical
Medicine according to the IMI/PharmaTrain syllabus (min
30 ECTS) (PharmaTrain, 2018) shall become the standard.
We believe that peer-to-peer learning and exchange with
colleagues from other areas of Pharmaceutical Medicine provide
additional value over purely internal courses at training sites.
In addition it aligns with the structure of the PharmaTrain
Specialist in Medicines Development Certification Program
(PharmaTrain, 2014).
The requirement for publication of an individual scientific
or clinical research work in a peer-reviewed journal for
the board-certification is currently debated. While the
competency of medical writing (including assessments
for medical information and preparation of regulatory
documents) is being well trained at the centers, there is
often limited opportunity to conduct original research.
To improve scientific exchange we intend to mandate
the participation in at least one meeting co-organized by
the SSPM during the time of the specialist training. These
meetings include the Annual Symposium in Pharmaceutical
Medicine co-sponsored with the Swiss Association of
Pharmaceutical Professionals (SwAPP), a 1 day event with
state-of-the-art lectures and discussions on current topics, or
the annual Spring Meeting organized by the Swiss Society
of Pharmacology and Toxicology (SSPT). The SSPT is
the umbrella organization of several scientific societies in
this field. The aim of this 1 day event is sharing original
scientific work, where active contribution is additionally
incentivized through awards.
Finally, we would like to pursue the idea of an “exchange”
program, where all trainees meet regularly for joint
sessions and rotate among the affiliated training centers.
During these half-day workshops, the trainee(s) elaborate
one or more specific case studies under the supervision
of the training head of the hosting center. The aim of
such sessions would be to share practice and working
experience between the different types of centers (e.g.,
academia- industry).
Defining the Swiss Catalog of Core
Competencies in Pharmaceutical
Medicine (SC3-PM)
During the recent accreditation process we have proposed
to evolve the current knowledge based curriculum to a
TABLE 1 | Proposed competency statements for a specialist in pharmaceutical
medicine (SPM) in Switzerland.
Domain Core competency statements
(1) Discovery of medicines and
early development
The SPM is able to identify unmet therapeutic
needs, evaluate the evidence for a new
candidate for clinical development and design a
Clinical Development Plan (CDP) for a Target
Product Profile (TPP).
(2) Clinical development and
clinical trials
The SPM is able to design, execute and
evaluate exploratory and confirmatory clinical
trials and prepare manuscripts or reports for
publication and regulatory submissions.
(3) Medicines regulation The SPM is able to interpret effectively the
regulatory requirements for the clinical
development of a new drug through the
product life-cycle to ensure its appropriate
therapeutic use and proper risk management
(4) Drug safety surveillance The SPM is able to evaluate the choice,
application and analysis of post-authorization
surveillance methods to meet the requirements
of national/international agencies for proper
information and risk minimization to patients
and clinical trial subjects.
(5) Ethics and subject
protection
The SPM is able to combine the principles of
clinical research and business ethics for the
conduct of clinical trials and commercial
operations within the organization.
(6) Socio-economics of the
healthcare system
The SPM is able to appraise the reasonable
development and use of diagnostic,
prophylactic and therapeutic means for the care
of healthy volunteers and patients, thereby
promoting the efficient use of available
resources within the legal boundaries.
(7) Communication and
management
The SPM is able to use the required skills for
effective communication and management
across stakeholders of the healthcare system,
including clinical setting (e.g., patients, care
givers, prescribers), competent authorities and
interdisciplinary teams at the workplace.
competency based curriculum. Therefore we are preparing
a Swiss Catalog of Core Competencies in Pharmaceutical
Medicine (SC3-PM) which adopts the concept of the IFAPP
core competency description based on applied knowledge,
skills and behaviors: We are currently adapting the proposed
content in the domains of (1) Discovery of Medicines and
Early Development, (2) Clinical Development and Clinical
Trials, (3) Medicines Regulation, (4) Drug Safety Surveillance,
(5) Ethics and Subject Protection, (6) Socio-Economics
of the Healthcare System, and (7) Communication and
Management (Table 1). Although refinement is still in
progress, we would like to share already some of the
thoughts and feedback received so far as part of the
initial consultation:
(a) The current IFAPP statements focus on specialists
(including non-physicians) working mainly on drug
development in industry. However, we are convinced
that the competencies have to equally apply to physician
specialists working in academic institutes or regulatory
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bodies. Hence, we are removing or replacing industry
specific aspects to reflect the broader scope. Particularly
competencies on commercial aspects shall be substituted
by a more socio-economic view on the healthcare
system, while business specific expertise can be acquired
through other post-graduate programs (e.g., Master of
Business Administration).
(b) We propose some revisions to better reflect the current
issues and topics beyond development of medicinal
products. Especially aspects on the competencies of a
specialist in Pharmaceutical Medicine to enable access to
medicines have been suggested. This includes expected
knowledge, skills and behaviors with respect to health
technology assessments and reimbursement. It also refers
to situations, where supply of medicines could be limited
or interrupted for various reasons. Further, we consider
strengthening the aspect of medical information and
appropriate communication with stakeholders along the
whole lifecycle of a medicinal product.
(c) Ensuring compliance with Swiss law and regulations
where appropriate.
CHALLENGES, PLAN OF ACTION,
LEARNINGS AND OUTLOOK
A defined post-graduate training path and qualification process
for physicians in Switzerland to obtain a recognized specialty
title in Pharmaceutical Medicine has become well established
in the course of the past 20 years. This has also recently been
validated by the FOPH’s re-accreditation process (Federal Office
of Public Health, 2018a). However, this requires adherence
to the general framework and certain operational aspects of
post-graduate training for all physicians in Switzerland. While
the concept for competency-based training was introduced by
the SIWF several years ago within the overarching ordinance
for physician post-graduate training, the IFAPP model now
helps us to better define targets for applied knowledge, skills
and behaviors regarding Pharmaceutical Medicine. Moving
forward, we believe that the currently defined tools [Mini-Clinical
Evaluation Exercise (Mini-CEX) and Direct Observation of
Procedural Skills (DOPS)] can be adapted and adequately used
for the required quarterly evaluation of the training progress
and acquired competencies (Swiss Institute for Post-Graduate
Training and Continuous Education, 2019b). At this stage we see
limited opportunities to deviate from the defined structures for
the final board examinations, other than possible adaptations in
the questions to further explore competencies in the dimensions
of “skills” and “behaviors.” We will also continue to implement
the structure and methodology provided by the SIWF for
evaluation and documentation of competencies as part of the
continuous professional development (Swiss Institute for Post-
Graduate Training and Continuous Education, 2019a).
Drug development and lifecycle management of both, new
and established medicinal products is a multidisciplinary
endeavor involving professionals with different educational
background in life sciences. The Swiss Association for
Pharmaceutical Professionals (SwAPP) provides to non-
physicians a similar 5-year certification program in
Pharmaceutical Medicine following the IFAPP/Pharmatrain
syllabus (Swiss Association of Pharmaceutical Professionals,
2019). Despite comparable expertise, certain clinical trial
related activities (e.g., clinical investigator) are restricted by law
to trained physicians.
FIGURE 1 | Illustration of the training curriculum and requirements to become board-certified specialist in Pharmaceutical Medicine in Switzerland.
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As a result of the accreditation process described initially,
the SSPM has formed a working group with the heads
of selected training centers to ensure regular exchange and
dialog with the aim to improve objectives and quality of the
vocational training across the different sites. We also intend
to leverage areas of special interest and expertise of the
various centers to allow for better exchange and peer-to-peer
learning through rotation programs for trainees. Furthermore,
this working group will serve as a platform to address
evolving training needs and adaptation of the curriculum,
namely for emerging trends such as personalized healthcare,
big data and artificial intelligence, as well as to address
new therapeutic approaches using gene-editing technologies.
Most importantly, we are on track for timely implementation
of this a new competency-based training curriculum for
Pharmaceutical Medicine in Switzerland to build up the next
generation of specialists.
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